Effects of Moringa peregrina Leaf Extracts on Benign Prostatic Hyperplasia in Rats

Mazhar Salim Al Zoubi, Wesam Al Khateeb,Musab El-Oqlah, Mu’ath, Migdady,Manl Issam Abu Al-Arja,Muna Bzour,Ahmad El-Oqlah, Samah, Almubarak, Mahmoud A Al-Qudah,Khalid Al-Batayneh,Michella Mkhael, Ahmed Elokda, Prawej Ansari,JMA Hannan,Mohamed M Nasef, Murtaza, M Tambuwala,Hamid A Bakshi

semanticscholar(2022)

引用 0|浏览1
暂无评分
摘要
Benign prostatic hyperplasia (BPH) is a non-cancerous enlargement of the prostate gland that can affect greater than 25% of males over 50 years old and the majority of males in their 80s (McVary, 2006). Once diagnosed, BPH has a negative health impact on the quality of life. Most of the current active clinical treatments in BPH involve procedural interventions accompanied by conventional treatments of beta-blockers and 5-alpha reductase inhibitors (5-ARIs) depending on the size of the prostate. Likewise, another treatment option includes the use of phosphodiesterase-5 (PDE-5) inhibitors (Clifford and Farmer 2000; Van Asseldonk et al., 2015). However, the current BPH treatments have been reported Abstract
更多
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要